You are viewing: US Digital PCR Market analysis
Part of: Digital PCR Market (Global)

The US Digital PCR Market was valued at $3324.6 Million in 2024 and projected to reach to $4774.7 Million by 2029, representing a compound annual growth rate of 7.5%. The US Digital PCR market is positioned for sustained growth through 2029, driven by increasing demand for highly sensitive and specific diagnostic solutions in clinical oncology and infectious disease testing.

US Digital PCR Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Digital PCR Market Trends and Insights

  • The US market benefits from advanced healthcare infrastructure, significant R&D investments, and widespread adoption of precision diagnostics across clinical and research laboratories.
  • Strong demand for accurate nucleic acid detection in oncology, infectious disease, and genetic testing applications is driving expansion throughout the US healthcare sector. The US Digital PCR market's 7.5% compound annual growth rate reflects increasing clinical validation, reimbursement support, and integration into routine diagnostic workflows.
  • US laboratories are increasingly adopting digital PCR technology for its superior sensitivity and absolute quantification capabilities compared to conventional qPCR methods.
  • Between 2024 and 2029, the US market will be shaped by technological innovations, expanding applications in liquid biopsy, and growing demand from both academic and commercial diagnostic centers across the country..

Key Market Statistics

  • CAGR (2024-2029) 7.5% CAGR
  • Market Size, 2024 ~USD 3324.6 Million
  • Forecast, 2029 ~USD 4774.7 Million
  • Country US

US Digital PCR Market Overview

Market Valuation :

The US Digital PCR market is valued at $3,324.6 million in 2024, with a projected CAGR of 7.5% through 2029, reaching $4,774.7 million by forecast end.

Healthcare Infrastructure Advantage :

Advanced US healthcare infrastructure, coupled with substantial R&D investments from leading institutions and biotech companies, drives widespread adoption of digital PCR technologies in clinical and research settings.

Clinical Application Growth :

Strong demand for accurate nucleic acid detection in oncology, infectious disease diagnostics, and genetic testing applications continues to expand the US market across hospital laboratories and diagnostic centers.

Precision Diagnostics Adoption :

Increasing adoption of precision medicine and personalized diagnostics in the US healthcare system accelerates digital PCR utilization for improved patient outcomes and treatment decisions.

US Digital PCR Market Dynamics

  • Regulatory support from the FDA, combined with reimbursement improvements for advanced molecular diagnostics, strengthens market expansion.
  • Investment in next-generation sequencing and companion diagnostics further propels adoption across major US healthcare systems and reference laboratories.
  • The market will benefit from technological innovations reducing costs and improving accessibility in smaller clinical facilities..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Qiagen N.V.
  • Agilent Technologies, Inc.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • The US Digital PCR market is valued at $3,324.6 million in 2024 and will reach $4,774.7 million by 2029, representing a 7.5% CAGR.
      • US adoption is driven by superior analytical performance, clinical validation, and integration into oncology and infectious disease diagnostics.
      • The US market benefits from robust reimbursement policies and strong demand from academic medical centers and commercial laboratories.
      • Technological advancements and expanding liquid biopsy applications will accelerate US market growth through 2029.

      Digital PCR Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DPCR (Offering)
      Forecast Period 2024–2029
      Growth Rate CAGR of 8.1% from 2024 to 2029
      Largest Segment QPCR (Offering)
      Market Size Base Year (Billions) ~USD 10.03 (2024)
      Revenue Forecast (Billions) ~USD 14.8 (2029)
      Segments Covered Offering, Type, Application, End User

      US Digital PCR Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Offering

      • Dpcr
      • Qpcr

      By Type

      • Beaming Digital Pcr
      • Blood Screening
      • Chip-Based Digital Pcr
      • Clinical Applications
      • Dpcr Instruments
      • Dpcr Reagents & Consumables
      • Droplet Digital Pcr
      • Environmental Applications
      • Forensic Applications
      • Gene Expression
      • Infectious Disease Testing
      • Oncology Testing
      • Other Clinical Applications
      • Other Dpcr Applications
      • Other Qpcr Applications
      • Other Research Applications
      • Qpcr Instruments
      • Qpcr Products
      • Qpcr Reagents & Consumables
      • Qpcr Services
      • Qpcr Software
      • Research Applications
      • Single-Cell Analysis
      • Stem Cell Research
      • Transplant Diagnostics

      By Application

      • Clinical Applications
      • Dpcr
      • Environmental Applications
      • Forensic Applications
      • Other Applications
      • Qpcr
      • Research Applications

      By End User

      • Academic & Research Institutes
      • Cros And Cdmos
      • Forensic Laboratories
      • Hospitals And Diagnostic Laboratories
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      US: QPCR MARKET, BY END USER, 2022–2029

      Segment20222023202420252026202720282029CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES506.6476.4496.4519.8547.6580.9621669.96.2
      CROS AND CDMOS305.9292.5309.1328.4350.9377.7409.7448.77.7
      FORENSIC LABORATORIES212.7208.6216.6226.1237.4250.9267.2287.25.8
      HOSPITALS AND DIAGNOSTIC LABORATORIES1656.11624.11729.21850.81992.62160.12360.32602.88.5
      OTHER END USERS204.58198.14203.62210.22218.18227.86239.68254.244.5
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES361.4353.1369.7389.1412439.2472511.96.7
      TOTAL3247.33152.83324.63524.43758.74036.74369.94774.77.5

      US: DPCR MARKET, BY END USER, 2022–2029

      Segment20222023202420252026202720282029CAGR (%)
      ACADEMIC & RESEARCH INSTITUTES63.663.267.472.277.884.392.1101.58.5
      CROS AND CDMOS37.7374043.547.652.458.16510.2
      FORENSIC LABORATORIES33.933.535.738.24144.448.453.28.3
      HOSPITALS AND DIAGNOSTIC LABORATORIES227.4227247.4270.9298.3330.5369.1415.810.9
      OTHER END USERS20.320.221.122.223.324.726.428.36
      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES49.44952.556.661.366.873.481.49.1
      TOTAL432.4429.9464.1503.5549.3603.2667.5745.29.9

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : US-based and international IVD companies need detailed market sizing and growth forecasts to develop digital PCR product portfolios, allocate R&D budgets, and plan US market entry or expansion strategies.
      • Clinical Laboratory Directors : Laboratory leaders require market insights on digital PCR adoption trends, clinical applications, and competitive offerings to make informed technology investments and improve diagnostic capabilities for US patients.
      • Healthcare Investment Firms : Private equity and venture capital investors targeting the US diagnostics sector need market data to evaluate digital PCR companies, assess growth potential, and identify acquisition or funding opportunities.
      • Pharmaceutical & Biotech Companies : US pharma and biotech firms developing companion diagnostics and precision medicine solutions require market intelligence on digital PCR adoption to support clinical trial strategies and commercialization planning.
      • Healthcare Consultants & Analysts : Management consultants and market analysts advising US healthcare organizations need comprehensive market data to support strategic recommendations, competitive analysis, and technology adoption roadmaps.

      Key Companies in the US Digital PCR Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited StatesPrivate CompanynCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna IVD and clinical assays,
      AFFYMETRIX INCUnited StatesPrivate CompanyGeneChip gene expression and genotyping arrays,CytoScan and OncoScan cytogenetics and oncology products,eBioscience antibodies, flow cytometry, and immunoassays,
      DECODE GENETICSIcelandPrivate CompanyInternal discovery for Amgen pipeline,External research collaborations and data services,Licensing of genetic discoveries and IP,
      DENVILLE SCIENTIFICUnited StatesPrivate CompanyPipetting systems and tips,Centrifuge tubes, plates, and sample storage,Molecular biology equipment and thermal cyclers,
      ROSETTA GENOMICSIsraelPublic CompanyRosettaGX Cancer Origin & mi-LUNG,RosettaGX Reveal (thyroid FNA),mi-KIDNEY and other microRNA classifiers,
      DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments, consumables, software),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      MERCK KGAAGermanyPublic CompanyLife Science (tools, reagents, bioprocessing, CDMO),Healthcare (prescription drugs, biopharmaceuticals),Electronics (semiconductor and display materials, equipment),
      QIAGEN N.V.NetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, SRH, transplant, viral load),PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions),
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics systems, reagents, and quality controls,Life Science instruments and reagents,Other and services (software, support, education, ancillary),
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments and cellular analysis devices,COVID-19 and other in vitro diagnostics,
      BECTON, DICKINSON, AND COMPANYUnited StatesPublic CompanyMedical Essentials (syringes, needles, catheters, sharps, vascular access),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions),
      ABBOTT LABORATORIESUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      MERIDIAN BIOSCIENCEUnited StatesPrivate CompanyMolecular reagents (PCR/RT-PCR enzymes, dNTPs, buffers, ready-to-use solutions, qPCR controls),Immunoassay raw materials (antigens, antibodies, interference blockers),Custom antibody and protein manufacturing services,
      BIOMÉRIEUXFrancePublic CompanyMicrobiology (culture media, BACT/ALERT VIRTUO, TEMPO, CHEMUNEX, BIOBALL, ENDONEXT),ID/AST Systems (VITEK 2, VITEK MS, VITEK REVEAL, API RANGE, ETEST, RAPIDEC CARBA NP),Molecular & Syndromic PCR (BIOFIRE, BIOFIRE SPOTFIRE, ARGENE, EMAG, NUCLISENS),
      EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies, Inc. is a U.S.-based private company founded in 2003 with 550 employees that develops molecular analysis platforms for life science research.

      AFFYMETRIX INC

      Affymetrix Inc. is a U.S. private company founded in 1991 with 1,150 employees that develops and manufactures molecular analysis tools and genomic platforms.

      DECODE GENETICS

      Decode Genetics is an Icelandic private company founded in 1996 with 331 employees engaged in genomic research and genetic analysis.

      DENVILLE SCIENTIFIC

      Denville Scientific is a U.S.-based private company founded in 1979 specializing in laboratory equipment and scientific supplies.

      ROSETTA GENOMICS

      Rosetta Genomics is an Israeli public company founded in 2000 with 86 employees focused on genomic and molecular diagnostics.

      DANAHER CORPORATION

      Danaher Corporation is a U.S.-based public company founded in 1969 with 59,000 employees operating a diversified conglomerate with significant life sciences and diagnostics divisions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a U.S.-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical instruments worldwide.

      MERCK KGAA

      Merck KGaA is a German public company founded in 1668 with 59,077 employees operating in pharmaceuticals, life sciences, and performance materials.

      QIAGEN N.V.

      QIAGEN N.V. is a Netherlands-based public company founded in 1984 with 5,500 employees specializing in molecular diagnostics and life sciences sample preparation.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a U.S.-based public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a U.S.-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japanese private company founded in 2002 with 1,779 employees specializing in molecular biology reagents and biotechnology products.

      BECTON, DICKINSON, AND COMPANY

      Becton, Dickinson, and Company is a U.S.-based public company founded in 1897 with 72,000 employees manufacturing medical devices, diagnostics, and laboratory equipment.

      ABBOTT LABORATORIES

      Abbott Laboratories is a U.S.-based public company founded in 1888 with 115,000 employees operating in diagnostics, pharmaceuticals, nutritional products, and medical devices.

      MERIDIAN BIOSCIENCE

      Meridian Bioscience is a U.S.-based private company founded in 1976 with 704 employees developing and manufacturing diagnostic products and reagents.

      BIOMÉRIEUX

      bioMérieux is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.

      EPPENDORF AG

      Eppendorf AG is a German private company founded in 1945 with 4,358 employees manufacturing laboratory equipment and consumables for life sciences research.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Obtain precise US market valuation ($3.3B in 2024) and verified CAGR projections (7.5%) to support investment decisions, business planning, and competitive positioning in the American digital PCR landscape.
      • Regional Opportunity Assessment : Identify high-growth clinical segments and geographic hotspots within the US market, including major metropolitan healthcare systems and emerging diagnostic centers driving digital PCR adoption.
      • Competitive Intelligence : Benchmark your US market performance against regional competitors, understand market share dynamics, and identify white space opportunities specific to American healthcare providers and laboratory networks.
      • Regulatory & Reimbursement Insights : Access US-specific regulatory pathways, FDA approval trends, and insurance reimbursement landscape for digital PCR technologies to optimize market entry and commercialization strategies.
      • Strategic Partnership Identification : Discover key US stakeholders, hospital systems, diagnostic laboratories, and research institutions actively adopting digital PCR for potential collaboration, distribution, or acquisition opportunities.

      Frequently asked questions

      What is the current size of the US Digital PCR market?

      The US Digital PCR market was valued at $3,324.6 million in 2024 and is expected to grow to $4,774.7 million by 2029.

      What is the growth rate of the US Digital PCR market?

      The US Digital PCR market is growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2029.

      What are the main drivers of growth in the US Digital PCR market?

      Key drivers include increasing adoption in oncology and infectious disease diagnostics, clinical validation, reimbursement support, and expansion of liquid biopsy applications across US laboratories.

      Which applications are most prevalent in the US Digital PCR market?

      The US market is dominated by oncology, infectious disease detection, genetic testing, and copy number variation analysis, with growing adoption in liquid biopsy and circulating tumor DNA applications.

      Who are the primary end-users of Digital PCR in the US?

      Primary end-users in the US include academic medical centers, clinical diagnostic laboratories, pharmaceutical companies, and contract research organizations conducting precision medicine and biomarker research.

      RESEARCH METHODOLOGY

      This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global digital PCR (dPCR) and real-time PCR (qPCR) market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the digital PCR (dPCR) and real-time PCR (qPCR) market. The secondary sources used for this study include World Bank, GLOBOCAN, World Health Organization (WHO), Eurostat, International Trade Administration, National Human Genome Research Institute (NHGRI, US), National Institutes of Health (NIH) (US), Institute for Health Metrics and Evaluation (US), US Food and Drug Administration (US FDA), Health Canada, European Medicines Agency (UK), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), European Medicines Agency (EMA), German Cancer Research Center, NHS (UK), Medicines and Healthcare Products Regulatory Agency (UK), Pharmaceuticals and Medical Devices Agency (Japan), Beijing Institute of Genomics (China), Ministry of Science & Technology (India), Ministry of Food and Drug Safety (South Korea), BioPlan Associates, Eurostat, and Factiva, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Extensive primary research was conducted after acquiring basic knowledge about the global digital PCR (dPCR) and real-time PCR (qPCR) market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

      The following is a breakdown of the primary respondents:

      Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the digital PCR (dPCR) and real-time PCR (qPCR) market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      Bottom-up Approach

      • The key players in the market have been identified through extensive secondary research.
      • The revenues generated from the digital PCR (dPCR) and real-time PCR (qPCR) business of leading players have been determined through primary and secondary research to arrive at the overall digital PCR (dPCR) and real-time PCR (qPCR) market.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      • Additionally, to arrive at the digital PCR (dPCR) and real-time PCR (qPCR) market for product segments, the PCR business shares of leading players for separate product category (wherever available) were also gathered from secondary sources. In some instances, the shares of PCR product businesses were ascertained through a detailed analysis of various parameters, including product portfolios, market positioning and primary insights.
      • All assumptions, approaches and individual shares/revenue estimates were validated through expert interviews.

      Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, and Share

      To know about the assumptions considered for the study, Request for Free Sample Report

      Top-down Approach

      After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

      Digital PCR (dPCR) and Real-time PCR (qPCR) Market Size, and Share

      Data Triangulation

      After arriving at the market size  from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Polymerase chain reaction (PCR) is a well-established technique used for the in vitro amplification of a given nucleotide (such as DNA). Digital polymerase chain reaction (digital PCR or dPCR) is a third-generation polymerase chain reaction technique that is used to clonally amplify and directly quantify nucleic acid strands, including DNA, cDNA, or RNA. Similarly, quantitative/real-time PCR (qPCR) is a well-established PCR technique that is widely utilized in DNA identification, amplification, and quantification. It involves the real-time analysis of reaction mixtures with the aid of fluorescent markers that are specific to either the end product or the reactant.

      Stakeholders

      • dPCR and qPCR product manufacturing companies
      • Third-party suppliers, direct suppliers, distributors, and channel partners
      • Venture capitalists and other public-private funding agencies
      • Healthcare service providers (including hospitals and diagnostic centers)
      • Pharmaceutical and biotechnology companies
      • Academic and research institutes
      • CROs & CDMOs
      • Forensic laboratories
      • Market research and consulting firms
      • Government and independent regulatory authorities

      Report Objectives

      • To define, describe, and forecast the digital PCR (dPCR) and real-time PCR (qPCR) market based on offering, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall digital PCR (dPCR) and real-time PCR (qPCR) market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the digital PCR (dPCR) and real-time PCR (qPCR) market and comprehensively analyze their product portfolios, market positions, and core competencies
      • To track and analyze competitive developments in the digital PCR (dPCR) and real-time PCR (qPCR) market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
      • To benchmark players within the digital PCR (dPCR) and real-time PCR (qPCR) market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

      Available Customizations

      With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

      Portfolio Assessment

      • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

      Company Information

      • Detailed analysis and profiling of additional market players (up to three).

      Geographical Analysis

      • A further breakdown of the Rest of Asia Pacific Digital PCR (dPCR) and real-time PCR (qPCR) market into countries
      • A further breakdown of the Rest of European Digital PCR (dPCR) and real-time PCR (qPCR) market into countries
      • A further breakdown of the Rest of Latin American Digital PCR (dPCR) and real-time PCR (qPCR) market into countries

      Get the Full Digital PCR Market Report

      Full forecast, segment splits, and company analysis for all Digital PCR Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status